Literature DB >> 184112

Inhibition of lymphoproliferation by hyperlipoproteinemic plasma.

C C Waddell, O D Taunton, J J Twomey.   

Abstract

Plasma for patients with primary type IV or V hyperlipoproteinemia inhibited [3H]thymidine incorporation by cultured mononuclear leukocytes. This previously unreported abnormality affected mononuclear leukocytes from patients with type IV or V hyperlipoproteinemia and from normal subjects. Patient cells incorporated [3H]thymidine normally when washed and incubated in medium containing normal plasma. Both spontaneous incorporation and stimulated incorporation in response to various mitogens and antigens were inhibited. The inhibitory effect was identified with the chylomicron and very low density lipoprotein fractions isolated from plasma and was concentration-dependent. Lectin used to stimulate cultured cells and [3H]thymidine used to measure responses were not bound to the lipoproteins in appreciable amounts. [3H]-Thymidine incorporation correlated well with morphologic evidence of lymphoproliferation. The mechanism of the inhibitory effect of type IV or V hyperlipoproteinemic plasma upon the response tested was not identified by may be related to interaction between lipoproteins and the cell membranes. We suggest that these lipoproteins may also interfere with the function of other cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184112      PMCID: PMC333258          DOI: 10.1172/JCI108548

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  IN-VITRO STUDIES OF LYMPHOCYTES FROM PATIENTS WITH SARCOIDOSIS AND LYMPHOPROLIFERATIVE DISEASES.

Authors:  K HIRSCHHORN; R R SCHREIBMAN; F H BACH; L E SILTZBACH
Journal:  Lancet       Date:  1964-10-17       Impact factor: 79.321

2.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

3.  Editorial: Viruses and arteriosclerosis.

Authors:  G E Burch
Journal:  Am Heart J       Date:  1974-04       Impact factor: 4.749

4.  The importance of type IV hyperlipoproteinemia as a predisposing factor in coronary artery disease.

Authors:  A F Salel; K Riggs; D T Mason; E A Amsterdam; R Zelis
Journal:  Am J Med       Date:  1974-12       Impact factor: 4.965

5.  Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

Authors:  L A Carlson; L E Böttiger
Journal:  Lancet       Date:  1972-04-22       Impact factor: 79.321

6.  Immunological observations in chronic mucocutaneous candidiasis.

Authors:  L Canales; R O Middlemas; J M Louro; M A South
Journal:  Lancet       Date:  1969-09-13       Impact factor: 79.321

7.  Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia.

Authors:  J J Twomey; C C Waddell; S Krantz; R O'reilly; P L'esperance; R A Good
Journal:  J Lab Clin Med       Date:  1975-06

8.  Hodgkin's disease. An immunodepleting and immunosuppressive disorder.

Authors:  J J Twomey; A H Laughter; S Farrow; C C Douglass
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

9.  Evidence for a monoclonal origin of human atherosclerotic plaques.

Authors:  E P Benditt; J M Benditt
Journal:  Proc Natl Acad Sci U S A       Date:  1973-06       Impact factor: 11.205

10.  Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.

Authors:  M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

View more
  8 in total

1.  Inhibition of lymphocyte proliferation stimulated by lectins and allogeneic cells by normal plasma lipoproteins.

Authors:  J H Morse; L D Witte; D S Goodman
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

2.  Immunostimulation. Clinical and experimental perspectives.

Authors:  J Drews
Journal:  Klin Wochenschr       Date:  1984-03-15

3.  Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus.

Authors:  F V Chisari; L K Curtiss; F C Jensen
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

4.  Oxidative modification of low density lipoprotein (LDL) by activated human monocytes and the cell lines U937 and HL60.

Authors:  M K Cathcart; G M Chisolm; A K McNally; D W Morel
Journal:  In Vitro Cell Dev Biol       Date:  1988-10

5.  Acetylated lipoproteins impair erythroid growth factor release from endothelial cells.

Authors:  N Dainiak; H B Warren; S Kreczko; M A Riordan; L Feldman; J Lawler; A M Cohen; P F Davies
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

6.  Effect of indomethacin on lymphocyte response to mitogens in puromycin aminonucleoside nephrosis in the rat.

Authors:  E H Garin; T M Barratt
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

7.  Plasma inhibition of lymphocyte proliferation in nephrotic syndrome: correlation with hyperlipidemia.

Authors:  C Lenarsky; S C Jordan; S Ladisch
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

8.  Multiple serum inhibitors of lectin-induced lymphocyte proliferation in nephrotic syndrome.

Authors:  A Martini; M A Vitiello; S Siena; V Capelli; A G Ugazio
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.